Cho Sung-Min, Canner Joe, Caturegli Giorgio, Choi Chun Woo, Etchill Eric, Giuliano Katherine, Chiarini Giovanni, Calligy Kate, Rycus Peter, Lorusso Roberto, Kim Bo Soo, Sussman Marc, Suarez Jose I, Geocadin Romergryko, Bush Errol L, Ziai Wendy, Whitman Glenn
Division of Neuroscience Critical Care, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
Division of Neuroscience Critical Care, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Crit Care Med. 2021 Jan 1;49(1):91-101. doi: 10.1097/CCM.0000000000004707.
Stroke is commonly reported in patients receiving venovenous extracorporeal membrane oxygenation, but risk factors are not well described. We sought to determine preextracorporeal membrane oxygenation and on-extracorporeal membrane oxygenation risk factors for both ischemic and hemorrhagic strokes in patients with venovenous extracorporeal membrane oxygenation support.
Retrospective analysis.
Data reported to the Extracorporeal Life Support Organization by 366 extracorporeal membrane oxygenation centers from 2013 to 2019.
Patients older than 18 years supported with a single run of venovenous extracorporeal membrane oxygenation.
None.
Of 15,872 venovenous extracorporeal membrane oxygenation patients, 812 (5.1%) had at least one type of acute brain injury, defined as ischemic stroke, hemorrhagic stroke, or brain death. Overall, 215 (1.4%) experienced ischemic stroke and 484 (3.1%) experienced hemorrhagic stroke. Overall inhospital mortality was 36%, but rates were higher in those with ischemic or hemorrhagic stroke (68% and 73%, respectively). In multivariable analysis, preextracorporeal membrane oxygenation pH (adjusted odds ratio = 0.10; 95% CI, 0.03-0.35; p < 0.001), hemolysis (adjusted odds ratio = 2.27; 95% CI, 1.22-4.24; p = 0.010), gastrointestinal hemorrhage (adjusted odds ratio = 2.01; 95% CI 1.12-3.59; p = 0.019), and disseminated intravascular coagulation (adjusted odds ratio = 3.61; 95% CI, 1.51-8.66; p = 0.004) were independently associated with ischemic stroke. Pre-extracorporeal membrane oxygenation pH (adjusted odds ratio = 0.28; 95% CI, 0.12-0.65; p = 0.003), preextracorporeal membrane oxygenation Po2 (adjusted odds ratio = 0.96; 95% CI, 0.93-0.99; p = 0.021), gastrointestinal hemorrhage (adjusted odds ratio = 1.70; 95% CI, 1.15-2.51; p = 0.008), and renal replacement therapy (adjusted odds ratio=1.57; 95% CI, 1.22-2.02; p < 0.001) were independently associated with hemorrhagic stroke.
Among venovenous extracorporeal membrane oxygenation patients in the Extracorporeal Life Support Organization registry, approximately 5% had acute brain injury. Mortality rates increased two-fold when ischemic or hemorrhagic strokes occurred. Risk factors such as lower pH and hypoxemia during the pericannulation period and markers of coagulation disturbances were associated with acute brain injury. Further research on understanding preextracorporeal membrane oxygenation and on-extracorporeal membrane oxygenation risk factors and the timing of acute brain injury is necessary to develop appropriate prevention and management strategies.
接受静脉-静脉体外膜肺氧合(VV-ECMO)治疗的患者中卒中较为常见,但风险因素尚未得到充分描述。我们试图确定接受VV-ECMO支持的患者发生缺血性卒中和出血性卒中的体外膜肺氧合前及体外膜肺氧合期间的风险因素。
回顾性分析。
2013年至2019年期间366个体外膜肺氧合中心向体外生命支持组织报告的数据。
接受单次VV-ECMO治疗且年龄大于18岁的患者。
无。
在15872例接受VV-ECMO治疗的患者中,812例(5.1%)发生了至少一种类型的急性脑损伤,定义为缺血性卒中、出血性卒中和脑死亡。总体而言,215例(1.4%)发生缺血性卒中,484例(3.1%)发生出血性卒中。总体住院死亡率为36%,但缺血性或出血性卒中患者的死亡率更高(分别为68%和73%)。多变量分析显示,体外膜肺氧合前pH值(校正比值比=0.10;95%置信区间,0.03-0.35;p<0.001)、溶血(校正比值比=2.27;95%置信区间,1.22-4.24;p=0.010)、胃肠道出血(校正比值比=2.01;95%置信区间1.12-3.59;p=0.019)和弥散性血管内凝血(校正比值比=3.61;95%置信区间,1.51-8.66;p=0.004)与缺血性卒中独立相关。体外膜肺氧合前pH值(校正比值比=0.28;95%置信区间,0.12-0.65;p=0.003)、体外膜肺氧合前氧分压(校正比值比=0.96;95%置信区间,0.93-0.99;p=0.021)胃肠道出血(校正比值比=1.70;95%置信区间,1.15-2.51;p=0.008)和肾脏替代治疗(校正比值比=1.57;95%置信区间,1.22-2.02;p<0.001)与出血性卒中独立相关。
在体外生命支持组织登记的接受VV-ECMO治疗的患者中,约5%发生急性脑损伤。发生缺血性或出血性卒中时死亡率增加两倍。诸如插管期间较低的pH值和低氧血症以及凝血紊乱标志物等风险因素与急性脑损伤相关。有必要进一步研究以了解体外膜肺氧合前及体外膜肺氧合期间的风险因素以及急性脑损伤的发生时间来制定合适的预防和管理策略。